Maximizing cost savings in heart failure management: The economic value of natriuretic peptide testing

Abstract

Heart failure (HF) remains a significant global health challenge, requiring cost-effective strategies to optimize patient outcomes and resource allocation. Natriuretic peptide (NP) testing has demonstrated substantial clinical and economic value in HF diagnosis, risk stratification, and management. This article examines the international evidence supporting NP testing, highlighting its role in reducing hospitalizations, optimizing medication use, and lowering healthcare expenditures. Addressing disparities in access and reimbursement policies can further enhance its adoption and impact across healthcare systems.

Keywords: Biomarker testing; Cost-effectiveness; Healthcare economics; Heart failure; NT-proBNP; Natriuretic peptides.